NEC Energy installs Europe’s largest battery storage system

first_img FacebookTwitterLinkedInEmailPrint分享Microgrid Knowledge:Boston-based NEC Energy Solutions (NEC) has completed installation of Europe’s largest battery system, 48-MW of energy storage that will provide reactive power in Germany to stabilize the transmission grid.NEC developed the project in Jardelund for German company EnspireME, a joint venture between Japan’s Mitsubishi and Eneco, a Netherlands-based renewable energy company. With 50 MWh of capacity, the system uses 10,000 lithium-ion battery modules, enough to store power for about 5,300 German households for 24 hours.The battery system can play multiple roles to strengthen the grid. It will earn revenue by serving the primary reserve market. This opportunity exists because Europe’s transmission system operators must secure a certain number of capacity reserves to prepare for sudden power loss or an extensive blackout.EnspireME will sell storage capacity to the German electricity market through weekly common auctions where European grid operators purchase reserve capacity to guarantee a 50 hertz frequency on the grid.The energy storage system can also take over the role of primary reserve provider and become a more sustainable alternative to coal and gas-fired plants. In addition, the project can serve local wind farms by allowing them to store excess electricity generated during periods when they cannot sell their output into markets because of excess supply.More: NEC installs Europe’s largest battery system NEC Energy installs Europe’s largest battery storage systemlast_img read more

Latest UK foot-and-mouth cases linked to earlier ones

first_imgSep 13, 2007 (CIDRAP News) – British officials who are investigating the latest outbreak of foot-and-mouth disease (FMD) said today that initials tests show the virus strain matches the strain found in outbreaks that surfaced in late July at two nearby farms. The focus of the outbreaks is an area in Surrey on the outskirts of London. The two earlier incidents are believed to have been caused by FMD virus that leaked from wastewater drains at a laboratory facility in nearby Pirbright. The facility houses a commercial FMD vaccine producer and a government-funded research institute. The United Kingdom’s Department for Environment, Food, and Rural Affairs (DEFRA), in a statement today, said initial virus sequencing indicates the virus in the new outbreak is type 01 BFS67, the same strain found in the earlier outbreaks. The latest cases were confirmed yesterday. In the two earlier FMD outbreaks, which were confirmed in early August, veterinary authorities culled nearly 600 animals to control the spread of the disease. A massive outbreak in Britain in 2001 led to the destruction of 7 million cattle to stop the disease. DEFRA said yesterday that animals on a farm next to the infected site would be destroyed as a precautionary measure. See also: Sep 12 CIDRAP News story “UK reports another foot-and-mouth outbreak” The current outbreak site is a farm near the town of Egham, about 10 miles from the two earlier outbreaks, the London Telegraph reported yesterday. Cattle on the farm were culled, and protection and surveillance zones were set up around the area, DEFRA reported. FMD is an extremely contagious disease that affects cattle, sheep, pigs, and other ruminants, causing sores in the mouth and on the hooves. The debilitating condition does not usually kill adult animals, but it drastically reduces milk production. The disease very rarely affects humans, according to DEFRA.last_img read more

THE PANDEMIC VACCINE PUZZLE Part 2: Vaccine production capacity falls far short

first_img “We have been working at the federal, state, even the local level to try to make sure this issue is visible,” he said. “To date, the results have been underwhelming.” “Everyone understands that if you don’t have vaccine you are dead in the water, but what has not been dealt with is that, if you don’t have the syringes and needles, the vaccine doesn’t do you any good,” said George Goldman, senior director for hypodermics at BD Medical Surgical Systems in Franklin Lakes, N.J. “Six hundred million devices, which is what in theory would be required to vaccinate the US population twice, is a very large volume if you plan for it and an even larger volume if you produce them in a reactive mode. We do not believe the industry is capable of producing that kind of volume in any short period of time under the best of circumstances” (see Bibliography: BD 2007). Food and Drug Administration (FDA) planners have accepted that, absent rapid changes in current flu-vaccine manufacturing techniques, delivering the earliest doses of a vaccine tuned to a newly emerged pandemic strain would take a minimum of 4 months (see Bibliography: Goodman 2006). A vaccine-industry scenario, described in August in the journal BioPharm International, goes out 6 months: 3 to 4 months to generate a seed strain, 4 to 6 weeks of manufacturing set-up, and 18 weeks of production, including 2 to 3 weeks of quality assurance and regulatory approval—all adding up to a vaccine product that would arrive roughly in time for the pandemic’s second wave but long after the first patients had recovered or died (see Bibliography: Thomas 2007). The nine countries—France, Germany, Italy, The Netherlands, Switzerland, the United Kingdom, the United States, Canada, and Australia—trade vaccine across borders but are unlikely to keep doing so in a pandemic, he added: “In 2000, a total of six western European companies distributed 66 million doses of vaccine to 18 western European countries. Only 42% of these doses were distributed within the countries that produced them; the remaining 58% were exported to other western European countries. For the rest of the world, about 40% of the doses used in central and eastern Europe, 60% of the doses used in the western Pacific and Southeast Asia, and virtually 100% of the doses used in Latin America, the eastern Mediterranean, and Africa were imported from one or more of the nine vaccine-producing developed countries” (see Bibliography: Fedson 2003). While the US government has taken initial steps to support manufacturers—witness the $133 million given to two manufacturers this past summer to retrofit existing plants and the $1 billion awarded for cell-culture research—much more is needed (see Bibliography: HHS 2006, 2007). What about vials and syringes? While vaccine manufacturers are likely grateful for the HHS funding, others in the industry say the investment is incomplete—because it does nothing to expand capacity for critical downstream tasks such as bottling and administering completed vaccine. But the more difficult obstacle is not the time needed to produce vaccine—which newer technologies such as cell culture could shorten to some degree—but the amount of vaccine needed. Despite years of work, the grave mismatch between predicted demand and likely supply has yet to be solved. Little incentive to buildMany experts have warned that the only way to expand flu-vaccine manufacturing capacity is to get governments to pay for it. In its 2004 “Consultation on priority public health interventions before and during an influenza pandemic,” the WHO cautioned: “Industry has little incentive to build additional manufacturing capacity, which requires very large long-term investments for an event that occurs only rarely and unpredictably.” (See Bibliography: WHO 2004) Last year, Britain’s Royal Society added bluntly: “It is not commercially viable for the vaccine industry to commit the necessary resources to scale up production in advance of a pandemic when there is no existing market, the threat of a pandemic may be years away and the risk in any single year may be considered to be low” (see Bibliography: Royal Society 2006). The pandemic vaccine puzzle Manufacturing 600 million syringes would take 2 years if manufacturers used only their existing excess capacity, Goldman said, and creating a new manufacturing line takes approximately a year. A vaccine embargo?The WHO analysis hides a number of highly optimistic assumptions, including zero glitches in production and 100% cooperation by regulators. But the greatest assumption may be that the newly produced pandemic vaccine would be distributed equitably to all comers around the globe. It is more likely that vaccine would never leave the countries where it is produced. The WHO plan asks countries that do not now use seasonal flu vaccine to launch new seasonal vaccination campaigns as a way of stimulating demand. It also asks countries with existing vaccination programs to increase vaccine use, so that 75% of those for whom vaccination is recommended are taking the shot. Both recommendations may be unrealistic: The United States, which uses more vaccine than any other nation, has never reached 75% uptake even among groups that are urged to take the shot because they are at high risk for flu complications. In the 2005-06 flu season, according to CDC data published in September, the highest acceptance of seasonal flu shots—69.3%—was among adults older than 64, who are considered “high risk” because of their age. Fifty- to 64-year-olds who are at high risk because of chronic medical conditions had a vaccination rate of 48.4%; only 32.3% of those in the same age range who had no high-risk conditions took the flu shot, and only 18.3% of healthy adults between 18 and 50 did so (see Bibliography: CDC 2007). The “fill-finish” sector—which puts bulk manufactured vaccine into vials or syringes—is not being asked to prepare for any excess capacity, said Jack Lysfjord, vice-president for pharmaceutical consulting in the Valicare division of Robert Bosch Packaging Technology Inc., in Brooklyn Park, Minn., a leading manufacturer of production and fill-finish equipment. “We are talking to some companies, but we are not hearing that they plan to buy twice as much from us in the next five years,” he said. “If they want to expand, they should be starting production now” because building an automated filling line can take 2 years (see Bibliography: Bosch 2007). “I have never believed that boosting seasonal flu-vaccine demand was the way to prepare for pandemic flu,” said Michael Osterholm, PhD, MPH, director of the University of Minnesota Center for Infectious Disease Research and Policy (CIDRAP), which publishes CIDRAP News, and of the National Institutes of Health (NIH)–funded Minnesota Center of Excellence for Influenza Research and Surveillance. “That economic model doesn’t work on its own and it has no scalability to provide flu vaccine for the rest of the world” (see Bibliography: Osterholm 2007). The companies that occupy the end of the vaccine-production process are also experiencing anxiety—on their own behalf and for the pharmaceutical manufacturers who feed product to them—that their operations will be disrupted by the start of a pandemic if they are brought into the process too late. In one example of the supply-demand mismatch, the United States plans to secure enough pandemic vaccine to deliver two doses to all 300 million of its residents (see Bibliography: FDA 2007: Committee meeting transcript). But current US manufacturing capacity tops out at 150 million 15-mcg doses, a total that is expected to rise to 250 million when a new Sanofi Pasteur plant comes online in 2008 (see Bibliography: Sanofi Pasteur 2007), but that still falls far short of the number the federal government hopes to deploy. And those hoped-for 600 million doses do not include the 40 million destined for the US pandemic stockpile that must be replaced periodically as flu strains mutate or the vaccine expires (see Bibliography: Riley 2007).center_img As a foreign-owned company, with its US unit in Minnesota and headquarters and manufacturing plants in Europe, Bosch feels this acutely. Much of the fill-finish equipment sold out of its US plant undergoes preliminary assembly in Germany, and many of the manufacturers for whom Bosch makes equipment rely on pharmaceutical ingredients or production components sourced from around the world. The same frustration is evident at BD (formerly Becton, Dickinson and Co.), the dominant company in syringe manufacturing. To be useful, those investments must be made well in advance of when vaccine is needed: The WHO estimates that building and licensing a new vaccine production line takes up to 5 years (see Bibliography: WHO 2004). The same scenario could happen again. “The U.S. will have a serious problem if the pandemic doesn’t strike in the next couple of years, because interest will decline and demand will go down again,” said Hedwig Kresse, an associate analyst for infectious diseases with the British-based market analysts Datamonitor. “Governments will have to guarantee a certain sales volume to keep [manufacturers] in the market and to keep these capacities up” (see Bibliography: Kresse 2007). Creating enough vaccine-manufacturing capacity to protect the world’s population is not cheap. The price tag is likely to be at least $2 billion and could rise to $9 billion, according to a WHO estimate (see Bibliography: WHO 2006: Global pandemic influenza action plan). Experts within the vaccine industry say that expecting manufacturers to make the investment asks companies to spend against their own best interest. “In the US market alone by the year 2010 there could be a surplus capacity resulting from ‘building for demand’ for pandemic preparedness but ‘suboptimal utilization’ based on significantly lesser demand for seasonal vaccines,” an engineer and two strategists from the Danish biotech firm NNE PharmaPlan wrote in the industry journal BioPharm International. “In Europe, Asia and the rest of the world, planned future capacities for ‘pandemic preparedness’ would have to address how potential surplus capacities can be effectively used in markets where there is little or no demand for seasonal vaccines” (see Bibliography: Thomas 2007). “If we really want to have surge capacity for pandemic vaccine, we have to invest in it like we do our oil reserves, or military reserve capacity,” Osterholm said. “The facilities may sit for years before they are utilized. But the analogy is having an airport fire department in case of a plane crash: You hope never to use it, but you invest as though it were a possibility” (see Bibliography: Osterholm 2007). Oct 26, 2007 (CIDRAP News) – The difficult reality is that, even if influenza science were perfect and research funding were abundant, achieving a widely deployable pandemic vaccine is currently out of reach. Chief among the reasons: The world lacks the manufacturing capacity to make enough vaccine to matter. “You have to think about every part of the components,” Lysfjord said. “The machines, the plants, the chemicals; the stopper, the glass, the aluminum overcast for the top of the vial; the labels. You’re not aware of how well-connected the system is until it breaks, and it is going to break big-time.” The United States has already experienced the aftermath of vaccine companies’ feeling overextended. Between 1998 and 2002, two of the four companies that then supplied seasonal flu vaccine left the market, citing losses on investment and increased regulatory demands. In the 2000-01 and 2003-04 flu seasons, the country experienced significant shortages of flu vaccine, with long lines, panic buying, price-gouging, and subsequent congressional investigations (see Bibliography: GAO 2001, 2004; Grady 2004). The World Health Organization’s (WHO’s) own best-case analysis, published in the agency’s 2006 “Global Pandemic Influenza Action Plan to Increase Vaccine Supply,” and updated in an Oct. 23, 2007, press release, breaks down the situation this way. In 2006, global manufacturing capacity for seasonal flu vaccine was 350 million doses per year of trivalent vaccine (comprising one 15-microgram [mcg] dose of each of three flu strains’ antigens). This year, according to the WHO, capacity could rise as high as 565 million doses, a total that incorporates both actual capacity increases achieved by manufacturers and theoretical capacity that would be created if manufacturing lines ran around the clock for the entire calendar year—something they do not do for seasonal flu-vaccine production. Given that a pandemic vaccine would be aimed at a single strain rather than three, global capacity could thus rise as high as 1.5 billion doses. But a pandemic vaccine would need to be given twice, because, unlike with seasonal flu, there would have been no prior exposure to the novel strain. So absent the use of adjuvants to stretch limited antigen supplies, industry could produce at best enough vaccine for 750 million people, far short of the amount needed to cover the world’s 6.7 billion inhabitants (see Bibliography: WHO 2006: Global influenza action plan; WHO 2007: Projected supply of pandemic influenza vaccine; Palkonyay 2007). The role of seasonal flu vaccine demandThe WHO action plan avers that manufacturers will significantly expand production capacity by 2012, largely because demand for seasonal flu vaccine will rise—but it offers no evidence that demand can be stimulated to levels that will persuade manufacturers to invest (see Bibliography: WHO 2006: Global pandemic influenza action plan). In the United States, for instance, the amount of vaccine manufactured has risen nearly every year, but so too has the amount returned to manufacturers unused. In the 2006-07 season, manufacturers selling to the US market delivered 120.9 million doses, the highest on record; they received back 18.4 million unused doses, also a record (see Bibliography: Santoli 2007). Editor’s note: This is the second in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame. Part 1 described how flu research has been a relatively low priority until very recently, which has left many important scientific questions unanswered. Seven hundred and fifty million “is fewer than the number of people that live in the nine countries that produce 85% of the world’s supply of flu vaccine,” said David Fedson, MD, a retired academic and vaccine-industry executive who has published critical analyses of pandemic-vaccine planning. “Which means that, if you live outside of a vaccine-producing country—whether that means Indonesia or Sweden or Spain—you get nothing” (see Bibliography: Fedson 2007: Author interview). Part 1: Flu research: a legacy of neglectPart 2: Vaccine production capacity falls far shortPart 3: H5N1 poses major immunologic challengesPart 4: The promise and problems of adjuvantsPart 5: What role for prepandemic vaccination?Part 6: Looking to novel vaccine technologiesPart 7: Time for a vaccine ‘Manhattan Project’?Bibliographylast_img read more

MEPC seeks £60m for Leavesden buildings

first_imgTo access this article REGISTER NOWWould you like print copies, app and digital replica access too? SUBSCRIBE for as little as £5 per week. Would you like to read more?Register for free to finish this article.Sign up now for the following benefits:Four FREE articles of your choice per monthBreaking news, comment and analysis from industry experts as it happensChoose from our portfolio of email newsletterslast_img

Barkley spurns Chelsea redemption

first_img(BBC) – Ross Barkley came off the bench to send Chelsea to Wembley as manager Frank Lampard’s half-time changes transformed this FA Cup quarter-final at Leicester City.The Foxes held sway in the first 45 minutes at the King Power Stadium, although it took a flying save from Leicester keeper Kasper Schmeichel to keep out Christian Pulisic’s powerful drive.Lampard’s discontent could be heard echoing around the virtually deserted arena – and he acted by introducing Barkley, Mateo Kovacic and Cesar Azpilicueta at the interval for Reece James, the subdued Billy Gilmour and Mason Mount.It had the desired effect as Chelsea improved markedly. Barkley, who was on target in the 2-0 win against Liverpool in the last round, scoring the winner after 63 minutes when he reacted to get in just ahead of Jonny Evans and sweep Willian’s clever cross past Schmeichel.Leicester, missing the injured James Maddison, were out of sorts after the break although they applied late pressure and defender Caglar Soyuncu was frustrated late on when his header struck Azpilicueta and flew over.Lampard’s reshuffle does the trickAn FA Cup quarter-final behind closed doors contains little of the passion and noise that usually accompanies these occasions, with a place in the last four at stake.It did, however, enable those few of us inside the ground to hear several loud blasts of “liven up, liven up” from Chelsea manager Lampard as he expressed his displeasure at his side’s early inability to cope with Leicester City’s bright start.Leicester failed to make the most of possession in the first 45 minutes and Lampard was able to make those substitutions that swung the game back in Chelsea’s favour.Talented youngster Billy Gilmour had one of those halves all young players can have, giving the ball away too much and having little impact – he will learn from this.Barkley came on and was Chelsea’s FA Cup talisman again, scoring the winner and almost adding a second in the last minute, forcing an unorthodox save from Schmeichel.It also demonstrated Chelsea’s squad strength as Lampard was able to introduce such experience and ability.Lampard and Chelsea have had an impressive re-start, winning at Aston Villa and getting a crucial three points at home to Manchester City in the Premier League. Those results kept them right on course for a top-four finish and now they are in an FA Cup semi-final at Wembley.Leicester’s lack of spark will worry RodgersLeicester’s City last game before the Premier League closed down as a result of the coronavirus pandemic in early March was an impressive 4-0 demolition of troubled Aston Villa at the King Power.It has been different since the re-start as they have struggled to draws at Watford and at home to Brighton before this disappointing FA Cup defeat.Manager Brendan Rodgers will have held high hopes of cup success after falling to Villa at the semi-final stage in the Carabao Cup – and this result and performance will have increased a few anxieties around the club.Leicester have had a superb season in the Premier League but they will be looking over their shoulders at Chelsea, who are a point behind them in fourth, as well as Wolves, who are only three points adrift – although they have played a game more.There was no doubt Leicester missed Maddison, out with a knock, as his link-up play with Vardy was sorely missed, the striker making his trademark runs but getting very little quality service.Leicester will remain optimistic and there is hardly any need to get carried away, but they need to re-discover the spark that made them such a potent force in the first seven months of this interrupted season.last_img read more

Survey suggests improving business conditions in Midwest

first_imgOMAHA, Neb. (AP) — A monthly survey report suggests that business conditions improved last month in nine Midwest and Plains states.The report issued Wednesday says the Mid-America Business Conditions Index rose to 55.2 in December from 54.1 in November. The October reading was 54.9.Creighton University economist Ernie Goss oversees the survey, and he says the shortages of skilled workers are still holding back even stronger growth.The survey results are compiled into a collection of indexes ranging from zero to 100. Survey organizers say any score above 50 suggests growth. A score below that suggests decline.The survey covers Arkansas, Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, Oklahoma and South Dakota.last_img read more